This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site)鈥�
- Investigator
- Jonathan A Chatzkel
- Ages
- 12 Years - N/A
- Sexes
- All